Baseline tumour size is an independent prognostic factor for overall survival in PD-L1 ≥ 50% non-small cell lung cancer patients treated with first-line pembrolizumab.
Baseline tumour size
Immune checkpoint inhibitor
Non-small cell lung cancer
Pembrolizumab
Journal
Cancer immunology, immunotherapy : CII
ISSN: 1432-0851
Titre abrégé: Cancer Immunol Immunother
Pays: Germany
ID NLM: 8605732
Informations de publication
Date de publication:
Jul 2022
Jul 2022
Historique:
received:
17
07
2021
accepted:
05
11
2021
pubmed:
29
11
2021
medline:
15
6
2022
entrez:
28
11
2021
Statut:
ppublish
Résumé
Advanced non-small cell lung cancer (NSCLC) with a PD-L1 tumour proportion score ≥ 50% can be treated with pembrolizumab alone. Our aim was to assess the impact of baseline tumour size (BTS) on overall survival (OS) in NSCLC patients treated with pembrolizumab versus chemotherapy. This retrospective, multicentre study included all patients with untreated advanced NSCLC receiving either pembrolizumab (PD-L1 ≥ 50%) or platinum-based chemotherapy (any PD-L1). The primary endpoint was the impact of BTS (defined as the sum of the dimensions of baseline target lesions according to RECIST v1.1 criteria) on OS. Between 09-2016 and 06-2020, 188 patients were included, 96 in the pembrolizumab (P-group) and 92 in the chemotherapy group (CT-group). The median follow-up was 26.9 months (range 0.13-37.91) and 44.4 months (range 0.23-48.62), respectively, while the median BTS was similar, 85.5 mm (IQR 57.2-113.2) and 86.0 mm (IQR 53.0-108.5), respectively (p = 0.42). The median P-group OS was 18.2 months [95% CI 12.2-not reached (NR)] for BTS > 86 mm versus NR (95% CI 27.2-NR) for BTS ≤ 86 mm (p = 0.0026). A high BTS was associated with a shorter OS in univariate analyses (p = 0.009) as well as after adjustment on confounding factors (HR 2.16, [95% CI 1.01-4.65], p = 0.048). The CT-group OS was not statistically different between low and high BTS patients, in univariate and multivariate analyses (p = 0.411). After adjustment on major baseline clinical prognostic factors, BTS was an independent prognostic factor for OS in PD-L1 ≥ 50% advanced NSCLC patients treated first-line with pembrolizumab.
Sections du résumé
BACKGROUND
BACKGROUND
Advanced non-small cell lung cancer (NSCLC) with a PD-L1 tumour proportion score ≥ 50% can be treated with pembrolizumab alone. Our aim was to assess the impact of baseline tumour size (BTS) on overall survival (OS) in NSCLC patients treated with pembrolizumab versus chemotherapy.
METHODS
METHODS
This retrospective, multicentre study included all patients with untreated advanced NSCLC receiving either pembrolizumab (PD-L1 ≥ 50%) or platinum-based chemotherapy (any PD-L1). The primary endpoint was the impact of BTS (defined as the sum of the dimensions of baseline target lesions according to RECIST v1.1 criteria) on OS.
RESULTS
RESULTS
Between 09-2016 and 06-2020, 188 patients were included, 96 in the pembrolizumab (P-group) and 92 in the chemotherapy group (CT-group). The median follow-up was 26.9 months (range 0.13-37.91) and 44.4 months (range 0.23-48.62), respectively, while the median BTS was similar, 85.5 mm (IQR 57.2-113.2) and 86.0 mm (IQR 53.0-108.5), respectively (p = 0.42). The median P-group OS was 18.2 months [95% CI 12.2-not reached (NR)] for BTS > 86 mm versus NR (95% CI 27.2-NR) for BTS ≤ 86 mm (p = 0.0026). A high BTS was associated with a shorter OS in univariate analyses (p = 0.009) as well as after adjustment on confounding factors (HR 2.16, [95% CI 1.01-4.65], p = 0.048). The CT-group OS was not statistically different between low and high BTS patients, in univariate and multivariate analyses (p = 0.411).
CONCLUSIONS
CONCLUSIONS
After adjustment on major baseline clinical prognostic factors, BTS was an independent prognostic factor for OS in PD-L1 ≥ 50% advanced NSCLC patients treated first-line with pembrolizumab.
Identifiants
pubmed: 34839373
doi: 10.1007/s00262-021-03108-x
pii: 10.1007/s00262-021-03108-x
doi:
Substances chimiques
Antibodies, Monoclonal, Humanized
0
B7-H1 Antigen
0
pembrolizumab
DPT0O3T46P
Types de publication
Journal Article
Multicenter Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
1747-1756Informations de copyright
© 2021. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.
Références
Bade BC, Dela Cruz CS (2020) Lung Cancer 2020. Clin Chest Med 41(1):1–24
doi: 10.1016/j.ccm.2019.10.001
Reck M, Rodríguez-Abreu D, Robinson AG, Hui R, Csőszi T, Fülöp A et al (2021) Five-Year Outcomes With Pembrolizumab Versus Chemotherapy for Metastatic Non–Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score ≥ 50%. J Clin Oncol 39(21):2339–2349
doi: 10.1200/JCO.21.00174
Reck M, Rodríguez-Abreu D, Robinson AG, Hui R, Csőszi T, Fülöp A et al (2016) Pembrolizumab versus Chemotherapy for PD-L1–Positive Non–Small-Cell Lung Cancer. N Engl J Med 375(19):1823–1833
doi: 10.1056/NEJMoa1606774
Planchard D, Popat S, Kerr K, Novello S, Smit EF, Faivre-Finn C et al (2018) Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 29:iv192–iv237
doi: 10.1093/annonc/mdy275
Yang F, Markovic SN, Molina JR, Halfdanarson TR, Pagliaro LC, Chintakuntlawar AV et al (2020) Association of Sex, Age, and Eastern Cooperative Oncology Group Performance Status With Survival Benefit of Cancer Immunotherapy in Randomized Clinical Trials: A Systematic Review and Meta-analysis. JAMA Netw Open 3(8):e2012534
doi: 10.1001/jamanetworkopen.2020.12534
El-Osta H, Jafri S (2019) Predictors for clinical benefit of immune checkpoint inhibitors in advanced non-small-cell lung cancer: a meta-analysis. Immunotherapy 11(3):189–199
doi: 10.2217/imt-2018-0086
Cortellini A, Tiseo M, Banna GL, Cappuzzo F, Aerts JGJV, Barbieri F et al (2020) Clinicopathologic correlates of first-line pembrolizumab effectiveness in patients with advanced NSCLC and a PD-L1 expression of ≥ 50%. Cancer Immunol Immunother 69(11):2209–2221
doi: 10.1007/s00262-020-02613-9
Buti S, Bersanelli M, Perrone F, Tiseo M, Tucci M, Adamo V et al (2021) Effect of concomitant medications with immune-modulatory properties on the outcomes of patients with advanced cancer treated with immune checkpoint inhibitors: development and validation of a novel prognostic index. Eur J Cancer 142:18–28
doi: 10.1016/j.ejca.2020.09.033
Doroshow DB, Bhalla S, Beasley MB, Sholl LM, Kerr KM, Gnjatic S et al (2021) PD-L1 as a biomarker of response to immune-checkpoint inhibitors. Nat Rev Clin Oncol 18(6):345–362
doi: 10.1038/s41571-021-00473-5
Joseph RW, Elassaiss-Schaap J, Kefford R, Hwu W-J, Wolchok JD, Joshua AM et al (2018) Baseline Tumor Size Is an Independent Prognostic Factor for Overall Survival in Patients with Melanoma Treated with Pembrolizumab. Clin Cancer Res 24(20):4960–4967
doi: 10.1158/1078-0432.CCR-17-2386
Tarantino P, Marra A, Gandini S, Minotti M, Pricolo P, Signorelli G et al (2020) Association between baseline tumour burden and outcome in patients with cancer treated with next-generation immunoncology agents. Eur J Cancer 139:92–98
doi: 10.1016/j.ejca.2020.08.026
Katsurada M, Nagano T, Tachihara M, Kiriu T, Furukawa K, Koyama K et al (2019) Baseline Tumor Size as a Predictive and Prognostic Factor of Immune Checkpoint Inhibitor Therapy for Non-small Cell Lung Cancer. Anticancer Res 39(2):815–825
doi: 10.21873/anticanres.13180
Sakata Y, Kawamura K, Ichikado K, Shingu N, Yasuda Y, Eguchi Y et al (2019) Comparisons between tumor burden and other prognostic factors that influence survival of patients with non-small cell lung cancer treated with immune checkpoint inhibitors. Thorac Cancer 10(12):2259–2266
doi: 10.1111/1759-7714.13214
Miyawaki T, Kenmotsu H, Mori K, Miyawaki E, Mamesaya N, Kawamura T et al (2020) Association Between Clinical Tumor Burden and Efficacy of Immune Checkpoint Inhibitor Monotherapy for Advanced Non–Small-Cell Lung Cancer. Clin Lung Cancer 21(5):e405–e414
doi: 10.1016/j.cllc.2020.02.012
Hakozaki T, Hosomi Y, Kitadai R, Kitagawa S, Okuma Y (2020) Efficacy of immune checkpoint inhibitor monotherapy for patients with massive non-small-cell lung cancer. J Cancer Res Clin Oncol 146(11):2957–2966
doi: 10.1007/s00432-020-03271-1
Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R et al (2009) New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1). Eur J Cancer 45(2):228–247
doi: 10.1016/j.ejca.2008.10.026
Heinze G, Wallisch C, Dunkler D (2018) Variable selection - A review and recommendations for the practicing statistician. Biom J 60(3):431–449
doi: 10.1002/bimj.201700067
Hopkins AM, Kichenadasse G, McKinnon RA, Rowland A, Sorich MJ (2019) Baseline tumor size and survival outcomes in lung cancer patients treated with immune checkpoint inhibitors. Semin Oncol 46(4–5):380–384
doi: 10.1053/j.seminoncol.2019.10.002
Belluomini L, Dodi A, Caldart A, Kadrija D, Sposito M, Casali M et al (2021) A narrative review on tumor microenvironment in oligometastatic and oligoprogressive non-small cell lung cancer: a lot remains to be done. Transl Lung Cancer Res 10(7):3369–3384
doi: 10.21037/tlcr-20-1134
Mentink JF, Paats MS, Dumoulin DW, Cornelissen R, Elbers JBW, Maat APWM et al (2021) Defining oligometastatic non-small cell lung cancer: concept versus biology, a literature review. Transl Lung Cancer Res 10(7):3329–3338
doi: 10.21037/tlcr-21-265
Kim C, Hoang CD, Kesarwala AH, Schrump DS, Guha U, Rajan A (2017) Role of Local Ablative Therapy in Patients with Oligometastatic and Oligoprogressive Non-Small Cell Lung Cancer. J Thorac Oncol Off Publ Int Assoc Study Lung Cancer 12(2):179–193
Amrane K, Geier M, Corre R, Léna H, Léveiller G, Gadby F et al (2020) First-line pembrolizumab for non–small cell lung cancer patients with PD-L1 ≥50% in a multicenter real-life cohort: The PEMBREIZH study. Cancer Med 9(7):2309–2316
doi: 10.1002/cam4.2806
Huang AC, Postow MA, Orlowski RJ, Mick R, Bengsch B, Manne S et al (2017) T-cell invigoration to tumour burden ratio associated with anti-PD-1 response. Nature 545(7652):60–65
doi: 10.1038/nature22079
Pauken KE, Wherry EJ (2015) Overcoming T cell exhaustion in infection and cancer. Trends Immunol 36(4):265–276
doi: 10.1016/j.it.2015.02.008
Mok TSK, Wu Y-L, Kudaba I, Kowalski DM, Cho BC, Turna HZ et al (2019) Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial. The Lancet 393(10183):1819–1830
doi: 10.1016/S0140-6736(18)32409-7
Smit E, Moro-Sibilot D, de Carpeño J, C, Lesniewski-Kmak K, Aerts J, Villatoro R, et al (2016) Cisplatin and carboplatin-based chemotherapy in the first-line treatment of non-small cell lung cancer: Analysis from the European FRAME study. Lung Cancer 92:35–40
doi: 10.1016/j.lungcan.2015.11.022
Gadgeel S, Rodríguez-Abreu D, Speranza G, Esteban E, Felip E, Dómine M et al (2020) Updated Analysis From KEYNOTE-189: Pembrolizumab or Placebo Plus Pemetrexed and Platinum for Previously Untreated Metastatic Nonsquamous Non–Small-Cell Lung Cancer. J Clin Oncol 38(14):1505–1517
doi: 10.1200/JCO.19.03136
Paz-Ares L, Vicente D, Tafreshi A, Robinson A, Soto Parra H, Mazières J et al (2020) A Randomized, Placebo-Controlled Trial of Pembrolizumab Plus Chemotherapy in Patients With Metastatic Squamous NSCLC: Protocol-Specified Final Analysis of KEYNOTE-407. J Thorac Oncol 15(10):1657–1669
doi: 10.1016/j.jtho.2020.06.015